Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.69 |
| ▸ | HTR2A | P28223 | 4/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9834626 | 0.90 | KMT2A (0.69) | DRD2HTR2ASIGMAR1KMT2AMEN1 | |
| SCHEMBL18770805 | 0.90 | DRD2 (0.82) | DRD2HTR2ASIGMAR1KMT2AMEN1 | |
| SCHEMBL7972984 | 0.84 | DRD2 (0.69) | DRD2HTR2ASIGMAR1KMT2AMEN1 | |
| SCHEMBL10722663 | 0.84 | DRD2 (0.69) | DRD2HTR2ASIGMAR1KMT2AMEN1 | |
| SCHEMBL771246 | 0.83 | MEN1 (0.64) | DRD2HTR2ASIGMAR1KMT2AMEN1 | |
| SCHEMBL16980657 | 0.83 | SIGMAR1 (0.72) | DRD2HTR2ASIGMAR1KMT2AMEN1 | |
| SCHEMBL15961276 | 0.83 | SIGMAR1 (0.91) | DRD2HTR2ASIGMAR1KMT2AMEN1 | |
| SCHEMBL2549342 | 0.83 | SIGMAR1 (0.72) | DRD2HTR2ASIGMAR1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL7983779 | 0.83 | DRD2 (0.68) | DRD2HTR2ASIGMAR1KMT2AMEN1 | |
| SCHEMBL1192814 | 0.82 | KMT2A (0.71) | DRD2HTR2ASIGMAR1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4599062-B2 | — | — | 2010-12-15 | — | — | JP | claimed |
| EP-1487444-B9 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-07-21 | — | — | EP | claimed |
| EP-1487444-B1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2009-12-30 | — | — | EP | claimed |
| US-20060052419-A1 | Use of pyridly amides as inhibitors of angiogenesis | ASTELLAS DEUTSCHLAND GMBH (DE) | 2006-03-09 | — | — | US | claimed |
| JP-2005528361-A | — | — | 2005-09-22 | — | — | JP | claimed |
| EP-1487444-A1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | Fujisawa Deutschland GmbH (DE) | 2004-12-22 | — | — | EP | claimed |
| WO-2003080054-A1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | FUJISAWA DEUTSCHLAND GMBH (DE) | 2003-10-02 | — | — | WO | claimed |
| EP-1348434-A1 | Use of pyridyl amides as inhibitors of angiogenesis | Fujisawa Deutschland GmbH (DE) | 2003-10-01 | — | — | EP | claimed |
| EP-1487444-B9 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-07-21 | — | — | EP | disclosed |
| EP-1487444-B1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2009-12-30 | — | — | EP | disclosed |
| US-20060052419-A1 | Use of pyridly amides as inhibitors of angiogenesis | ASTELLAS DEUTSCHLAND GMBH (DE) | 2006-03-09 | — | — | US | disclosed |
| EP-1487444-A1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | Fujisawa Deutschland GmbH (DE) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003080054-A1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | FUJISAWA DEUTSCHLAND GMBH (DE) | 2003-10-02 | — | — | WO | disclosed |
| EP-1348434-A1 | Use of pyridyl amides as inhibitors of angiogenesis | Fujisawa Deutschland GmbH (DE) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052419-A1 | Use of pyridly amides as inhibitors of angiogenesis | FLT1, VEGFA, FLT4 | DRD2 4246/4885HTR2A 2225/4885SIGMAR1 3828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.